Activity Outline FDA Grand Rounds: Closer to Zero December 9, 2021 Virtual - Adobe Platform

Activity Coordinator:

Madison Hanson (Madison.Hanson@fda.hhs.gov), Rokhsareh Shahidzadeh (rokhsareh.shahidzadeh@fda.hhs.gov), Sharron Watson (Sharron.Watson@fda.hhs.gov),

Series Description

The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.

Lecture Description

FDA's Closer to Zero initiative is the agency's action plan for reducing exposure to toxic elements, including lead, arsenic, cadmium, and mercury, in foods for babies and young children. Closer to Zero utilizes a multi-phase, science-based, iterative approach for achieving continual improvements over time, laying out plans to further reduce the levels of toxic elements in foods. The plan includes advancing research and evaluation of changes in dietary exposures to toxic elements, setting action levels, encouraging adoption of best practices by industry, increasing targeted compliance and enforcement activities, and monitoring progress of levels over time.

References

- Closer to Zero: Action Plan for Baby Foods. (2021). Retrieved from https://www.fda.gov/food/metals-and-your-food/closer-zero-action-plan-baby-foods
- Flannery, B. M., Dolan, L. C., Hoffman-Pennesi, D., Gavelek, A., Jones, O. E., Kanwal, R., Wolpert, B., Gensheimer, K., Dennis, S., & Fitzpatrick, S. (2020). U.S. Food and Drug Administration's interim reference levels for dietary lead exposure in children and women of childbearing age. Regulatory toxicology and pharmacology: RTP, 110, 104516. https://doi.org/10.1016/j.yrtph.2019.104516
- Dolan, L. C., Flannery, B. M., Hoffman-Pennesi, D., Gavelek, A., Jones, O. E., Kanwal, R., Wolpert, B., Gensheimer, K., Dennis, S., & Fitzpatrick, S. (2020). A review of the evidence to support interim reference level for dietary lead exposure in adults. Regulatory toxicology and pharmacology: RTP, 111, 104579. https://doi.org/10.1016/j.yrtph.2020.104579
- Gavelek, A., Spungen, J., Hoffman-Pennesi, D., Flannery, B., Dolan, L., Dennis, S., & Fitzpatrick, S. (2020).
 Lead exposures in older children (males and females 7-17 years), women of childbearing age (females 16-49 years) and adults (males and females 18+ years): FDA total diet study 2014-16. Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment, 37(1), 104–109.
 https://doi.org/10.1080/19440049.2019.1681595
- Spungen J. H. (2019). Children's exposures to lead and cadmium: FDA total diet study 2014-16. Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment, 36(6), 893–903. https://doi.org/10.1080/19440049.2019.1595170

Series Objectives

- Discuss the research conducted at the FDA
- Explain how FDA science impacts public health

Learning Objectives After completion of this activity, the participant will be able to:

- Discuss why lead, arsenic, cadmium, and mercury are present in foods.
- Explain the challenges of reducing the presence of the contaminants in foods.
- Identify the difference between a reference level of exposure to a contaminant and an action level for a contaminant in foods.
- Examine the various of activities the FDA participates in to support the Closer to Zero initiative.

Target Audience

This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency external scientific communities.

Agenda

Lecture 1 December 9, 2021

		Time	Topic	Speaker
--	--	------	-------	---------

Continuing Education Accreditation



In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit*(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-21-016-L04-P for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

Choiniere, Conrad, PhD, Director, Office of Analytics and Outreach, FDA Center for Food Safety and Applied Nutritiomothing to disclose

Planning Committee

- □ Dinatale, Miriam, Team Leader, Food and Drug Administration nothing to disclose
- □ Pfundt, Tiffany, PharmD, Pharmacist, FDA nothing to disclose
- " Wheelock, Leslie, RN, MS, Director, OSPD, FDA, OC, OCS, OSPD nothing to disclose

CE Consultation and Accreditation Team

- \blacksquare Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD nothing to disclose \blacksquare Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD nothing to disclose

Registration Fee and RefundsRegistration is complimentary, therefore refunds are not applicable.